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Summary
QUESTIONS UNDER STUDY: Even today, some patients
with laryngeal cancer present with airway obstruction ne-
cessitating an intervention in the form of either a tracheo-
stomy or transoral laser debulking (TOL). Controversy ex-
ists as to whether such an intervention is a risk factor for
poor oncological or functional outcome in patients who
then undergo primary (chemo)radiotherapy.
METHODS: Retrospective chart review of all patients un-
dergoing primary curative nonsurgical treatment for T3/T4
laryngeal squamous cell cancer at the University Hospital
Zurich between 1981 and 2011.
RESULTS: A total of 29/114 patients had an airway in-
tervention before initiation of (chemo)radiotherapy (21/29
tracheostomies, 8/29 TOL). Kaplan-Meier analysis showed
no statistical difference in oncological outcomes between
the groups with and without intervention (5 year overall
survival: 52% vs 70%, disease specific survival: 73% vs
79%, recurrence free survival: 53% vs 63%). In functional
terms, we report an overall functional larynx rate of 60%.
CONCLUSIONS: Airway intervention was not found to be
a risk factor for poor oncological or functional outcome in
this patient group.
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Introduction
In the western world, laryngeal cancer was until recently
the most common noncutaneous cancer of the head and
neck [1]. It is now the second most common after the recent
precipitous increase in oropharyngeal cancers.
Traditionally, treatment for advanced laryngeal cancer was
a total laryngectomy. However, after the landmark Depart-
ment of Veterans Affairs study [2] in 1991 and subsequent
studies [3], many centres worldwide now treat all but the
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most advanced tumours with primary (chemo)radiotherapy,
saving surgical treatment in the form of total laryngectomy
for residual or recurrent disease or only the most bulky
primary disease. This “organ preserving” approach is be-
lieved to achieve similar oncological outcomes to a
primary surgical approach, with the benefit of retained
laryngeal function for breathing, speaking and swallowing.
Selection of patients for either primary
(chemo)radiotherapy or primary total laryngectomy is nor-
mally made in a tumour board setting and depends on local
protocols, expertise and, of course, patient choice. One
factor which is weighed in the balance is whether the pa-
tient has had to have an airway intervention prior to definit-
ive treatment. Even with good access to medical care, some
patients’ first presentation of their laryngeal cancer will be
with acute airway obstruction, necessitating an emergency/
urgent airway intervention. This airway intervention is life-
saving in the short term and often performed outside of
head and neck cancer centres by noncancer specialists. Pa-
tients are then referred on for definitive treatment of their
laryngeal cancer. The Tumour Board must then decide if
the airway intervention has disrupted/seeded the primary
cancer and decide how this would influence the decision as
the primary treatment modality.
For patients who undergo primary (chemo)radiotherapy,
there also exists the possibility of requiring airway inter-
vention either during or after their (chemo)radiotherapy.
For example, tumour oedema from (chemo)radiotherapy
may compromise the airway during therapy. There are also
a few patients who, despite a satisfactory oncological out-
come, have a nonfunctioning larynx and may require per-
manent tracheostomy or even laryngectomy potentially
months or even years after the (chemo)radiation was com-
pleted.
The aim of this study was to retrospectively analyse a co-
hort of patients undergoing primary nonsurgical treatment
for laryngeal cancer and see how many patients required
an airway intervention, when it was performed, and what
form this took (tracheostomy or transoral laser debulking
[TOL]). Special emphasis is placed on patients who under-
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went airway intervention prior to definitive treatment and
results are expressed in terms of both oncological and func-
tional outcomes.
Materials and methods
A retrospective case note review was performed of all pa-
tients who underwent primary curative non-surgical treat-
ment for T3/T4 laryngeal squamous cell cancer at the
University Hospital Zurich between 1981 and 2011. Pa-
tients with less advanced disease, treated primarily with an-
other modality or treated with palliative intent from the be-
ginning, were excluded.
Patients’ demographic, staging, treatment and outcome
data were collected with use of electronic patient records.
Staging was based on both a clinical and a radiological ex-
amination of the patient and both versions 6 and 7 of the
American Joint Committee on Cancer (AJCC) manual [4]
were used as the study period straddled the change in 2009.
Airway interventions in the form of tracheostomy or TOL
were recorded, as was the date of eventual reversal of the
tracheostomy if this was done. Patients who suffered from
residual or recurrent disease were also recorded, along with
their management.
All patients were discussed in our tumour board meeting
and underwent primary nonsurgical treatment. Over such a
long time-period one can imagine that the tumour board’s
attitude to surgery or nonsurgical treatment changed. Anec-
dotally, it is probably fair to say that the more recent pa-
tients were more likely to have (chemo)radiotherapy than
surgery, even those with advanced disease. Ultimately, the
patients also have the final decision as to which treatment
they will choose. Also of note, for patients with T4 disease
and cartilage involvement, surgical treatment was recom-
mended. The radiotherapy protocols evolved during the
study period, notably with the advent of intensity modu-
lated radiation therapy (IMRT) in March 2002 (consecut-
ively since June 2003). All patients after this date were
treated with IMRT, all those before underwent traditional
multiplanar external beam radiotherapy. Details of the ex-
act regimen have been published elsewhere [5].
Patients undergoing tracheostomy had this performed in
the traditional open manner in all cases. No percutaneous
tracheostomies were performed. Transoral debulking was
performed using a CO2 laser. The indication for a tracheo-
stomy was the same regardless of whether it was pre-,
during or post- definitive treatment, i.e., a compromised
airway with either inadequate ventilation or recurrent aspir-
ation.
In terms of oncological outcomes, local recurrence (LR)
was defined as either residual or recurrent squamous cell
cancer (SCC) of the larynx or level 6. Regional recurrence
(RR) was defined as either residual or new disease in the
lateral neck, levels 1–5. Distant recurrence (DR) was dia-
gnosed on imaging studies unless with possibility for cyto-
logical/histological confirmation existed.
Statistical analysis of overall survival (OS), disease spe-
cific survival (DSS), local recurrence-free survival (LRFS)
and regional recurrence-free survival (RRFS) was calcu-
lated using the Kaplan-Meier method. The log-rank test
was used for univariate analysis (SPSS, Chicago, Illinois,
v21) and Pearson’s chi-squared or Fisher’s exact test for
comparison of subgroups, as appropriate.
Functional outcomes are expressed as descriptive statistics
of how many patients were able to be weaned off their
tracheostomies, how many patients had permanent tracheo-
stomies and how many progressed to total laryngectomy.
Results
A total of 114 patients (106 men, 8 women) were included
in this study. Median age at diagnosis was 62 years. A more
detailed description of patients and extent of disease can be
found in table 1, which also compares the nonairway inter-
vention group with the airway intervention group.
Oncological outcomes and timing of airway
intervention
For the cohort as a whole, 5 year OS, DSS, LRFS were
65%, 78% and 56% respectively (fig. 1). Only 4/114 pa-
tients had evidence of disease less than 4 months after the
end of primary therapy, implying that they had residual tu-
mours that had been incompletely treated (persistent dis-
ease). A further 43/114 patients had recurrence of disease
>6 months after end of therapy. Forty of 47 recurrences
occurred within the first 2 years after initial therapy. Re-
currences were treated with total laryngectomy (33/47 pa-
tients), neck dissection (1/47 patient) or palliative therapies
(13/47).
Figure 1
Five-year (60-month) comparison of overall survival (OS), disease
specific survival (DSS) and local recurrence-free survival (LRFS).
Note that the LRFS lies under the other two curves, indicating that
despite local recurrence, patients can often be successfully
salvaged.
Figure 2
Pretreatment airway intervention vs no airway intervention: 5-year
survival.
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Twenty-nine of the 114 patients had an airway intervention
before commencement of radiotherapy (21/29 tracheo-
stomies, 8/29 laser debulking [TOL]). One of these patients
initially had an unsuccessful TOL which needed to be con-
verted to a tracheostomy. During treatment, a further 3/114
patients had tracheostomy performed. After completion of
treatment 19 patients underwent tracheostomy, and 5 pa-
tients had TOL.
No intervention vs predefinitive therapy airway
intervention
To ensure that our comparison between the intervention
and nonintervention groups was unbiased, we analysed the
demographics and disease burden of the two groups to en-
sure comparability. Where 2x2 tables could be constructed,
a two-tailed Fischer’s exact test was used, otherwise Pear-
son’s chi-squared test (table 1). This showed no signific-
ant differences in terms of age, gender or disease burden
between the two groups.
Kaplan Meier survival analysis was then performed to
compare the oncological outcomes in the two groups. No
statistically significant differences in 5 year OS (70% vs
52%, p = 0.176), DSS (79% vs 73%, p = 0.768) and LRFS
(58% vs 50%, p = 0.661) between no airway intervention
vs pre-therapy airway intervention was found (fig. 2).
Pretreatment tracheostomy vs no tracheostomy / TOL
In the predefinitive therapy setting, it might be argued that
there are fundamental differences between endoscopic ap-
proaches to securing the airway such as TOL and the in-
tuitively more “risky” tracheostomy. The latter might cut
directly into the tumour, seeding the tract and also runs the
risk of disrupting lymphatics. Furthermore, the AJCC sta-
ging does not necessarily capture the subtleties of tumour
burden and perhaps tracheostomies are still performed on
the more severely affected patients, despite our negative
chi-squared and Fischer’s tests outlined above. We there-
fore performed an analysis of the 21 patients undergoing
pretherapy tracheostomy against the remaining 93 patients
(i.e. those with TOL or no intervention). Once again, no
statistically difference in disease burden or demographics
was found between the two groups. Five-year LRFS was
51.3% vs 54.5% for the no-tracheostomy vs tracheostomy
groups respectively (p = 0.633).
Functional outcomes
In total, 43/114 of patients had a tracheostomy at some
stage of their treatment (21 pretreatment, 3 during treat-
ment and 19 after). Thirteen of the 43 patients were able
to be successfully weaned from their tracheostomies, 19/43
ultimately had a laryngectomy and 11/43 can be deemed to
have a permanent tracheostomy despite an anatomical in-
tact larynx (table 2).
Despite the initially “organ-preserving” approach, 46/114
(40%) patients ultimately lost their laryngeal function, res-
ulting in 35 laryngectomies and 11 permanent tracheostom-
ies. Whilst 33/35 laryngectomies were performed for onco-
logical reasons, 2/35 were performed for purely functional
reasons without any sign of cancer. For the cohort as a
whole we therefore have a “functional larynx” rate of 68/
114 (60%). Of the patients who needed pretherapy tracheo-
stomy, this “functional larynx” rate was 12/21 (57%) and
for patients undergoing no pretherapy intervention of 56/93
(60%).
Discussion
Laryngeal cancer is the second most common noncu-
taneous cancer of the head and neck. Cure rates are excel-
lent for early disease, but problematic in more advanced
disease. Indeed, laryngeal cancer is the only cancer for
which survival outcomes have worsened in the last 20 years
[1]. Many reasons have been put forward to explain this,
including the increasing use of primary nonsurgical therapy
[6].
Table 1: Comparison of patients and disease characteristics between intervention and non-intervention groups.





Female 6 2 1 8Gender
Male 79 27 106
<60 37 10 0.389 47Age
>60 47 20 67
T3 58 19 0.678 77
T4 25 10 35
cT-stage
T4b 1 1 2
N0 54 22 0.358 76
N1 9 4 13
N2a 2 0 2
N2b 4 3 7
N2c 12 1 13
cN-stage
N3 3 0 3
III 47 19 0.772 66
IVa 33 10 43
Stage
IVb 4 1 5
Glottic 28 10 0.649 38
Supraglottic 41 17 58
Subglottic 2 1 3
Site
Transglottic 13 2 15
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Organ-preserving treatment of laryngeal cancer aims to
achieve the same oncological outcomes as surgical ap-
proaches with the benefit of maintaining laryngeal function
(speech and swallow). Laser ablation for T1 tumours or
partial laryngectomies for more advanced tumours are sur-
gical possibilities, but (chemo)radiotherapy is currently the
most widespread treatment modality, especially since the
advent of IMRT. Advances continue apace with dose paint-
ing being the latest innovation leading many units and pa-
tients to prefer a primarily nonsurgical approach to laryn-
geal cancer in all but the most advanced cases. In a few
centres worldwide, organ-preserving surgery in the form of
transoral robotic surgery (TORS) is once again being pre-
ferred to (chemo)radiotherapy.
Before deciding which treatment to recommend a patient,
the tumour board must carefully decide the oncological
risks and the functional risks. These questions must be
answered not only before the start of treatment but
throughout the patient’s management. For example, one
key question is how to identify those patients who are
nonresponders to (chemo)radiotherapy as early as possible.
Our unit, in common with many others, use a positron
emission tomography / computed tomography (PET-CT)
scan at 3 months post-treatment, but ideally, some form of
test during or even before the treatment would be far better
(e.g. diffusion-magnetic resonance imaging [MRI], PET-
CT).
One factor which might push tumour boards towards a
surgical management plan is an antecedent airway inter-
vention. It seems plausible that patients who have presen-
ted with airway obstruction and needed some form of sur-
gical intervention might have sub-optimal outcomes with
(chemo)radiotherapy and might therefore be more appro-
priately treated with a total laryngectomy with adjuvant
radiotherapy. A recent publication showed that an ante-
cedent airway intervention followed by primary total laryn-
gectomy with adjuvant radiotherapy was not associated
with adverse outcomes [7]. So if antecedent airway in-
tervention was associated with increased risk in primary
(chemo)radiotherapy patients then the message would be
clear: patients with antecedent airway interventions should
be counselled towards a primary surgical treatment.
Overall the literature in this area is confusing. Many art-
icles have discussed the possibility of tumour inoculation
[8] or seeding [9] during intubation [10], tracheostomy
[11] or other operative manipulation of a laryngeal tumour.
Some articles find that tracheostomy is a risk factor
[12–14] whilst others find no increased risk [7, 15, 16].
The picture is further confused as studies often suffer from
heterogeneous patient groups (for example mixing primary
and salvage laryngectomies together) or from small sample
size (for example fewer than 100 patients).
Furthermore, the key question, namely, if the patient has an
antecedent airway intervention, what should the definitive
management plan be, is not addressed. The airway inter-
vention is often a “given” and may have been performed in
non-head and neck units outside of normal hours as a life-
saving procedure. To simply tell the patients that they are
possibly at increased oncological risk does not seem partic-
ularly helpful.
We purposively picked a highly homogeneous patient
group in order to answer a very specific question. Do pa-
tients with antecedent airway intervention undergoing
primary nonsurgical treatment have worse outcomes than
those without the antecedent airway intervention? Our data
would suggest that there is no increased risk, though we ac-
cept the limitations of the retrospective nature of our data
and small sample size. It is however in keeping with the
largest series looking at this problem from Zhao et al. [15]
(548 patients) and Petrovic et al. [16] (402 patients), who
could also find no increased risk.
During treatment, some patients whose airway was initially
deemed safe, suffer radiation-induced swelling which fur-
ther reduces the diameter of the already compromised air-
way and necessitates airway intervention. This was the
situation for three of our patients and, unfortunately, our
data show that such circumstances are fore-bears of a dis-
mal outcome.
The last group of patients who need tracheostomy after
completing radiotherapy often require it because of an as-
piration risk as much as for ventilation. These patients can
sometimes be helped with intensive swallow physiotherapy
and develop tricks to minimise their aspiration risk. Some
however will find their voice next to useless and their as-
piration risk so high as to justify a total laryngectomy for
functional reasons. This was the case for 2/114 patients.
Having answered our primary oncological question, we
have also looked at functional results associated with ante-
cedent airway intervention. Overall, we report a functional
larynx rate of 60% for the cohort as a whole is fairly similar
to published figures (which often include less advanced
cancers) [2, 3].
Table 2: Overview Any Recurrence free survival and functional larynx rate.
Airway intervention Tracheostomy Debulking Recurrence-free survival (%) Functional larynx
rate (%)
None
n = 58 (51%)
63 61
Pretherapy airway intervention
n = 29 (25%)
21 8 53 54
During therapy airway intervention
n = 3 (3%)
3 0
Post-therapy airway intervention




n = 114 (100%)
43 13 61 60
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Conclusions
Our data would suggest that pre(chemo)radiotherapy air-
way intervention, whether in the form of tracheostomy or
TOL does not negatively impact on oncological outcome.
This adds to the considerable debate on this topic as many
surgeons instinctively feel that it must increase risk.
In terms of functional outcomes, we report that of 114 pa-
tients initially undergoing primary nonsurgical treatment,
33 needed laryngectomy for oncological control, 2 for
frozen larynx and a further 11 will remain tracheostomy de-
pendent. This latter group may have a preserved larynx, but
it is unfortunately, nonfunctional. This gives a “functional”
larynx rate of 68/114 (60%) which is similar to other pub-
lished figures [2, 3].
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Figures (large format)
Figure 1
Five-year (60-month) comparison of overall survival (OS), disease specific survival (DSS) and local recurrence-free survival (LRFS). Note that
the LRFS lies under the other two curves, indicating that despite local recurrence, patients can often be successfully salvaged.
Figure 2
Pretreatment airway intervention vs no airway intervention: 5-year survival.
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